8
Jun
2026

City Therapeutics Pockets $99.5M, Advances RNAi Candidates to the Clinic

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Corsera Health, Led by Maraganore and Meanwell, Aims to Prevent Heart Disease
Creating a New Class of Medicines: John Maraganore on The Long Run
In Support of FDA’s Authority to Regulate Medicines
Remote/Hybrid Work is Here to Stay. Biotech Should Embrace It